Cargando…

2550. Comparing Efficacy of Serum and Epithelial Lining Fluid Concentrations for Meropenem Against Carbapenem-Resistant Enterobacterales

BACKGROUND: Carbapenem-resistant Enterobacterales are a CDC urgent threat and need effective free drug concentrations at sites of infection such as epithelial lining fluid (ELF) for pneumonia. Therefore, it’s the goal of this study to compare efficacy of meropenem serum and ELF concentrations while...

Descripción completa

Detalles Bibliográficos
Autores principales:	Lavoie, Thomas, Daffinee, Katie, Pogue, jason M, Achour, Brahim, LaPlante, Kerry L
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2023
Materias:	Abstract
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10678282/ http://dx.doi.org/10.1093/ofid/ofad500.2167

Ejemplares similares

Impact of minocycline, polymyxin B, meropenem, and amikacin on growth-prevention of Acinetobacter baumannii with various biofilm-forming capabilities
por: Beganovic, Maya, et al.
Publicado: (2017)

620. Sub-MIC Concentrations of Levofloxacin and Delafloxacin Enhance Staphylococcus aureus Biofilm Formation: Significance of Maximizing Exposure
por: Bodo, Emily C, et al.
Publicado: (2019)

Treatment Options for Carbapenem-Resistant Enterobacteriaceae Infections
por: Morrill, Haley J., et al.
Publicado: (2015)

Microbiology of Meropenem-Vaborbactam: A Novel Carbapenem Beta-Lactamase Inhibitor Combination for Carbapenem-Resistant Enterobacterales Infections
por: Bhowmick, Tanaya, et al.
Publicado: (2020)

1559. Ertapenem Plus Ceftriaxone or Ceftaroline Dual Β-Lactam Combination for Enterococcus faecalis
por: Cusumano, Jaclyn A, et al.
Publicado: (2019)

1323. Substantial Doses of Daptomycin and Rifampin Eradicate S. epidermidis Biofilm in an In Vitro Pharmacodynamic (IVPD) Model
por: Piehl, Emily C, et al.
Publicado: (2020)

Effect of Colistin, Fosfomycin and Meropenem/Vaborbactam on Carbapenem-Resistant Enterobacterales in Egypt: A Cross-Sectional Study
por: Shrief, Raghdaa, et al.
Publicado: (2022)

Meropenem-Vaborbactam Activity against U.S. Multidrug-Resistant Enterobacterales Strains, Including Carbapenem-Resistant Isolates
por: Shortridge, Dee, et al.
Publicado: (2023)

Meropenem-Vaborbactam Activity against Carbapenem-Resistant Enterobacterales Isolates Collected in U.S. Hospitals during 2016 to 2018
por: Castanheira, Mariana, et al.
Publicado: (2020)

Activity of meropenem/vaborbactam and comparators against non-carbapenemase-producing carbapenem-resistant Enterobacterales isolates from Europe
por: Shortridge, Dee, et al.
Publicado: (2022)

Overview of meropenem-vaborbactam and newer antimicrobial agents for the treatment of carbapenem-resistant Enterobacteriaceae
por: Petty, Lindsay A, et al.
Publicado: (2018)

1218. Activity of Meropenem-Vaborbactam and Comparator Agents Against Carbapenemase-Negative, Carbapenem-Resistant Enterobacterales from US Hospitals
por: Castanheira, Mariana, et al.
Publicado: (2021)

In Vitro Activity of Imipenem-Relebactam, Meropenem-Vaborbactam, Ceftazidime-Avibactam and Comparators on Carbapenem-Resistant Non-Carbapenemase-Producing Enterobacterales
por: Bonnin, Rémy A., et al.
Publicado: (2023)

848. Trends of Carbapenem Resistance in Enterobacterales in the US Between 2015 and 2019
por: Marcella, Stephen, et al.
Publicado: (2020)

Performance Evaluation of BD Phoenix NMIC-413 Antimicrobial Susceptibility Testing Panel for Imipenem, Meropenem, and Ertapenem Against Clinical Carbapenem-Resistant and Carbapenem-Susceptible Enterobacterales
por: Zhang, Jingjia, et al.
Publicado: (2021)

Real-world, Multicenter Experience With Meropenem-Vaborbactam for Gram-Negative Bacterial Infections Including Carbapenem-Resistant Enterobacterales and Pseudomonas aeruginosa
por: Alosaimy, Sara, et al.
Publicado: (2021)

202. Comparative Activity of Ceftazidime-Avibactam, Imipenem-Relebactam and Meropenem-Vaborbactam Tested Against Carbapenem-Nonsusceptible Enterobacterales that Are Carbapenemase-Negative
por: Castanheira, Mariana, et al.
Publicado: (2021)

699. Relationship Between Klebsiella pneumoniae Antimicrobial Resistance and Biofilm Formation
por: Cusumano, Jaclyn, et al.
Publicado: (2018)

1114. Exploring bactericidal activity and emergence of resistance for carbapenem-resistant Enterobacterales (CRE) with and without Klebsiella pneumoniae carbapenemase (KPC) treated with optimized meropenem (MEM) and meropenem-vaborbactam (MEV) exposures
por: Squires, Kevin M, et al.
Publicado: (2023)

Curcumin-meropenem synergy in carbapenem resistant Klebsiella pneumoniae curcumin-meropenem synergy
por: Gülen, Dumrul, et al.
Publicado: (2021)

Cefiderocol, a Siderophore Cephalosporin, as a Treatment Option for Infections Caused by Carbapenem-Resistant Enterobacterales
por: Kaye, Keith S., et al.
Publicado: (2023)

2560. Individual Meropenem Epithelial Lining Fluid and Plasma PK/PD Target Attainment in Patients with Pneumonia
por: Rohani, Roxane, et al.
Publicado: (2023)

Activity of mecillinam against carbapenem-resistant Enterobacterales
por: Emeraud, Cécile, et al.
Publicado: (2022)

Updates on the Status of Carbapenem-Resistant Enterobacterales in Lebanon
por: Fadlallah, Mahdi, et al.
Publicado: (2023)

Screening for Metallo-Beta-Lactamases Using Non-Carbapenem Agents: Effective Detection of MBL-Producing Enterobacterales and Differentiation of Carbapenem-Resistant Enterobacterales
por: Takei, Kentarou, et al.
Publicado: (2023)

Clinical Outcomes and Safety of Meropenem–Colistin versus Meropenem–Tigecycline in Patients with Carbapenem-Resistant Acinetobacter baumannii Pneumonia
por: Park, Jae-Min, et al.
Publicado: (2021)

Proposal: a study of $\overline{p}$p reactions in BEBC at 25,50 and 100 (?) GeV/c
por: Apostolakis, Alcibiades J, et al.
Publicado: (1974)

An Overview on Phenotypic and Genotypic Characterisation of Carbapenem-Resistant Enterobacterales
por: Rabaan, Ali A., et al.
Publicado: (2022)

The carbapenem inoculum effect provides insight into the molecular mechanisms underlying carbapenem resistance in Enterobacterales
por: Cartagena, Alexis Jaramillo, et al.
Publicado: (2023)

Synergistic Activity of Equol and Meropenem against Carbapenem-Resistant Escherichia coli
por: Kim, Hye-Rim, et al.
Publicado: (2021)

The Place of Meropenem–Vaborbactam in the Management of Carbapenem-Resistant Gram-Negative Infections
por: Chopra, Teena
Publicado: (2021)

Molecular characterization of clinical carbapenem-resistant Enterobacterales from Qatar
por: Abid, Fatma Ben, et al.
Publicado: (2021)

Molecular epidemiology of carbapenem-resistant Enterobacterales in Thailand, 2016–2018
por: Paveenkittiporn, Wantana, et al.
Publicado: (2021)

Poor outcomes in both infection and colonization with carbapenem-resistant Enterobacterales
por: Howard-Anderson, Jessica R., et al.
Publicado: (2022)

Molecular epidemiology and outcome of carbapenem-resistant Enterobacterales in Saudi Arabia
por: Alraddadi, Basem M., et al.
Publicado: (2022)

Monitoring Carbapenem-Resistant Enterobacterales in the Environment to Assess the Spread in the Community
por: Urase, Taro, et al.
Publicado: (2022)

Early Years of Carbapenem-Resistant Enterobacterales Epidemic in Abu Dhabi
por: Pál, Tibor, et al.
Publicado: (2022)

Risk Factors for Carbapenem-Resistant Enterobacterales Clinical Treatment Failure
por: Rebold, Nicholas, et al.
Publicado: (2023)

Carbapenem-Resistant and ESBL-Producing Enterobacterales Emerging in Central Texas
por: Parker, Jennifer K, et al.
Publicado: (2023)

A Review of Carbapenem Resistance in Enterobacterales and Its Detection Techniques
por: Caliskan-Aydogan, Oznur, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_n0kbhlbstr9r28caquai5cqf25